BridgeBio Pharma, Inc. · NASDAQ:BBIO
BridgeBio Pharma — Technical Presentation (September 2024)
18 slides from BridgeBio Pharma's technical presentation, Sep 30, 2024
Slide 1: Encaleret (CLTX-305) Normalizes Mineral Homeostasis Parameters in ADH1 over 24 Months
Encaleret (CLTX-305) Normalizes Mineral Homeostasis Parameters in Patients with Autosomal Dominant Hypocalcemia Type 1 over 24 months in a Phase 2 Study (NCT04581629) RI Gafni1, IR Hartley1, KL Roszko1, EF Nemeth2, KA Pozo1, AS Mathew3, MS Roberts3, SH Adler3, MT Collins1 1. NIDCR, NIH, Bethesda, MD
Slide 2: Disclosures
Disclosures This study was supported by a public/private partnership between the NIDCR Intramural Research Program and BridgeBio affiliate Calcilytix Therapeutics, Inc. Encaleret is currently under clinical development, and its safety and efficacy have not been evaluated by any regulatory authority.
Slide 3: Blood calcium is maintained by four organs regulated by the CaSR and PTH
Blood calcium is maintained by four organs regulated by the CaSR and PTH Ca2+ = ionized calcium; PTH = parathyroid hormone; CaSR = calcium-sensing receptor 3
Slide 4: Activating variants in the CASR cause Autosomal Dominant Hypocalcemia Type 1 (ADH1)
Activating variants in the CASR cause Autosomal Dominant Hypocalcemia Type 1 (ADH1) Activating variants in the CASR Hypersensitive CaSR causes Clinical Manifestations increase tissue sensitivity to Ca2+ dysregulation of Ca homeostasis Parathyroid Acute symptoms Wild PTH Secretion PTH Decreased PTH s
Slide 5: Encaleret, an investigational oral calcilytic, may be a potential treatment for ADH1
Encaleret, an investigational oral calcilytic, may be a potential treatment for ADH1 Parathyroid Kidney ▪ Encaleret is an investigational negative allosteric modulator of the ADH1 Wild type ADH1 Wild type CaSR that can decrease CaSR Ca2+ Excretion PTH Secretion sensitivity to extracellular calcium C
Slide 6: Phase 2B Study Design – CLTX-305-201
Encaleret Phase 2B Study Design – CLTX-305-201 Period 1 1 Period 2 1 Period 3 LTE Individualized Individualized Outpatient Long-term dose escalation dose titration extension extension (LTE) 5 days, inpatient (N=6) 5 days, inpatient (N=13) 24 weeks, outpatient (N=13) Outpatient (N=12) Month 18 LTE Re
Slide 7: Baseline Characteristics
Baseline Characteristics Characteristic Study Population (N = 13) Normal Range Age, mean, yr (range) 39 (22-60) Female, n (%) 8 (62%) Corrected Calcium1,2 (mg/dL) 7.1 ± 0.4 8.4 –10.2 Intact PTH (pg/mL) 6.3 ± 7.8 15 – 65 Phosphate (mg/dL) 4.5 ± 1.1 2.3 – 4.7 Magnesium (mg/dL) 1.7 ± 0.2 1.6 – 2.6 24h
Slide 8: Phase 2B Oral Encaleret Dosing Summary
Phase 2B Oral Encaleret Dosing Summary Individual Patient Dosing Period 3 (n=13) Encaleret sulfate dose (mg/day) 360 Optimized dose adjustments Week 24 Mean+SD: 172±140 mg/day 270 180 LTE (n=12) Maintenance dose 90 Month 18 Mean+SD: 151±133 mg/day 0 5 1 2 3 4 6 8 12 16 20 24 3 6 9 12 15 18 y k k a W
Slide 9: Encaleret was well-tolerated with no serious adverse events reported
Encaleret was well-tolerated with no serious adverse events reported Periods 2 and 3 LTE N=13 N=13 Number of subjects experiencing any Serious Adverse Event 0 (0%) 0 (0%) Number of subjects experiencing any Treatment-Emergent 13 (100%) 12 (92%) Adverse Event (TEAE) Mild 13 (100%) 12 (92%) Moderate 2
Slide 10: Encaleret normalized mean iPTH and blood calcium over a 24-month period
Encaleret normalized mean iPTH and blood calcium over an 24-month period 100 75 ** (pg/mL) ** iPTH 50 25 0 0 8 16 24 3 36 6 48 9 60 12 72 15 84 18 96 11 10 ** ** Blood cCa (mg/dL) 9 8 7 6 0 8 16 24 36 3 48 6 60 9 72 12 84 15 96 18 Period 3 LTE Weeks Months Data reported as mean+SD. Values below limi
Slide 11: Encaleret decreased mean urine calcium into the normal range
Encaleret decreased mean urine calcium into the normal range 800 600 (mg/24 h) Urine Ca 400 ** ** 200 0 0 8 16 24 36 3 48 6 60 9 72 12 84 15 96 18 Period 3 LTE Weeks Months No progression of renal calcifications on ultrasound observed at Period 3 Week 24 or LTE Month 12 Data reported as mean+SD. Val
Slide 12: Encaleret decreased mean blood phosphate and increased mean blood magnesium
Encaleret decreased mean blood phosphate and increased mean blood magnesium 6 5 Phosphate ** ** (mg/dL) 4 3 2 1 0 0 8 16 24 36 3 48 6 60 9 72 12 84 15 96 18 3 Magnesium ** ** 2 (mg/dL) 1 0 0 8 16 24 36 3 48 6 60 9 72 12 84 15 96 18 Period 3 LTE Weeks Months Data reported as mean+SD. Gray shading ref
Slide 13: Encaleret increased bone turnover markers
Encaleret increased bone turnover markers 5 CTX Relative to ULN 4 (CTX/ULN) 8/12 participants >1 3 at LTE Month 18 2 1 0 0 8 16 24 36 3 48 6 60 9 72 12 84 15 96 18 6 P1NP Relative to ULN 5 (P1NP/ULN) 4 5/12 participants >1 3 at LTE Month 18 2 1 0 0 8 16 24 36 3 48 6 60 9 72 12 84 15 96 18 Period 3 L
Slide 14: Encaleret had minimal short-term effects on bone density
Encaleret had minimal short-term effects on bone density Screening Z-score Period 3, Week 24 LTE, Month 12 DXA Anatomical Site Mean ± SD Z-score Mean ± SD Z-score Mean ± SD n = 11 (n = 11) (n = 11) (n = 10) Total Body 2.1 ± 1.4 2.0 ± 1.3 N/A AP Lumbar Spine 2.6 ± 1.5 2.3 ± 1.7 2.5 ± 1.7 Total Hip 2.
Slide 15: Summary
Summary ▪ In patients with ADH1, encaleret administered twice daily rapidly corrects and maintains mineral homeostasis within the normal range, as demonstrated by: ✓ Increase in PTH ✓ Correction of hypocalcemia ✓ Normalization of mean 24-hr urine calcium ✓ Reduction in mean blood phosphate ✓ Increas
Slide 16: Acknowledgements
Acknowledgements Thanks to the patients, referring physicians, and the support staff at the National Institutes of Health 16
Slide 17: Back-up Slide
Back-up Slide
Slide 18: Period and LTE bone turnover markers
Period 3 and LTE bone turnover markers 5 CTX Relative to ULN 4 (CTX/ULN) 3 5 2 001 4 1 002 003 3 0 004 0 8 16 24 36 48 60 72 84 96 2 005 006 1 6 P1NP Relative to ULN 007 0 5 008 (P1NP/ULN) 0 8 16 24 3 36 6 48 9 60 12 72 15 84 18 96 4 009 010 3 011 2 012 1 013 0 0 8 16 24 36 3 48 6 60 9 72 12 84 15 9
BridgeBio Pharma — Technical Presentation (September 2024) on 6ix